Global Short-acting Recombinant Human Erythropoietin Drugs Market Growth 2026-2032
The global Short-acting Recombinant Human Erythropoietin Drugs market size is predicted to grow from US$ 10550 million in 2025 to US$ 16410 million in 2032; it is expected to grow at a CAGR of 6.6% from 2026 to 2032.
Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.
The market for short-acting recombinant human erythropoietin drugs is currently in a steady growth phase, with its size gradually expanding, and sales continuing to rise. These drugs find extensive use in the treatment of anemia, especially in patients with chronic kidney disease, cancer chemotherapy recipients, and individuals requiring correction of hemoglobin levels pre-surgery. Future developments may include further expansion into additional clinical applications and more convenient administration routes, along with improved manufacturing techniques to meet the growing healthcare demands.
LP Information, Inc. (LPI) ' newest research report, the “Short-acting Recombinant Human Erythropoietin Drugs Industry Forecast” looks at past sales and reviews total world Short-acting Recombinant Human Erythropoietin Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Short-acting Recombinant Human Erythropoietin Drugs sales for 2026 through 2032. With Short-acting Recombinant Human Erythropoietin Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Short-acting Recombinant Human Erythropoietin Drugs industry.
This Insight Report provides a comprehensive analysis of the global Short-acting Recombinant Human Erythropoietin Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Short-acting Recombinant Human Erythropoietin Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Short-acting Recombinant Human Erythropoietin Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Short-acting Recombinant Human Erythropoietin Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Short-acting Recombinant Human Erythropoietin Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Short-acting Recombinant Human Erythropoietin Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.
The market for short-acting recombinant human erythropoietin drugs is currently in a steady growth phase, with its size gradually expanding, and sales continuing to rise. These drugs find extensive use in the treatment of anemia, especially in patients with chronic kidney disease, cancer chemotherapy recipients, and individuals requiring correction of hemoglobin levels pre-surgery. Future developments may include further expansion into additional clinical applications and more convenient administration routes, along with improved manufacturing techniques to meet the growing healthcare demands.
LP Information, Inc. (LPI) ' newest research report, the “Short-acting Recombinant Human Erythropoietin Drugs Industry Forecast” looks at past sales and reviews total world Short-acting Recombinant Human Erythropoietin Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Short-acting Recombinant Human Erythropoietin Drugs sales for 2026 through 2032. With Short-acting Recombinant Human Erythropoietin Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Short-acting Recombinant Human Erythropoietin Drugs industry.
This Insight Report provides a comprehensive analysis of the global Short-acting Recombinant Human Erythropoietin Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Short-acting Recombinant Human Erythropoietin Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Short-acting Recombinant Human Erythropoietin Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Short-acting Recombinant Human Erythropoietin Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Short-acting Recombinant Human Erythropoietin Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Short-acting Recombinant Human Erythropoietin Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Epoetin-alfa
- Epoetin-beta
- Darbepoetin-alfa
- Others
- Anemia
- Kidney Disorders
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Amgen
- Johnson & Johnson
- Roche
- Kyowa Kirin
- LG Chem
- Daewoong Pharmaceutical
- Wockhardt
- CJ Healthcare
- 3SBio
- Kexing Biopharm
- Harbin Pharmaceutical Group
- Beijing Four Rings Bio-Pharmaceutical
- What is the 10-year outlook for the global Short-acting Recombinant Human Erythropoietin Drugs market?
- What factors are driving Short-acting Recombinant Human Erythropoietin Drugs market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Short-acting Recombinant Human Erythropoietin Drugs market opportunities vary by end market size?
- How does Short-acting Recombinant Human Erythropoietin Drugs break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Short-acting Recombinant Human Erythropoietin Drugs by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Short-acting Recombinant Human Erythropoietin Drugs by Country/Region, 2021, 2025 & 2032
2.2 Short-acting Recombinant Human Erythropoietin Drugs Segment by Type
2.2.1 Epoetin-alfa
2.2.2 Epoetin-beta
2.2.3 Darbepoetin-alfa
2.2.4 Others
2.2.5 Short-acting Recombinant Human Erythropoietin Drugs Sales by Type
2.2.5.1 Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2021-2026)
2.2.5.2 Global Short-acting Recombinant Human Erythropoietin Drugs Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Type (2021-2026)
2.3 Short-acting Recombinant Human Erythropoietin Drugs Segment by Application
2.3.1 Anemia
2.3.2 Kidney Disorders
2.3.3 Others
2.3.4 Short-acting Recombinant Human Erythropoietin Drugs Sales by Application
2.3.4.1 Global Short-acting Recombinant Human Erythropoietin Drugs Sale Market Share by Application (2021-2026)
2.3.4.2 Global Short-acting Recombinant Human Erythropoietin Drugs Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Short-acting Recombinant Human Erythropoietin Drugs Breakdown Data by Company
3.1.1 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Sales by Company (2021-2026)
3.1.2 Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Company (2021-2026)
3.2 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Revenue by Company (2021-2026)
3.2.1 Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Company (2021-2026)
3.2.2 Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Company (2021-2026)
3.3 Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Company
3.4 Key Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Product Location Distribution
3.4.2 Players Short-acting Recombinant Human Erythropoietin Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR SHORT-ACTING RECOMBINANT HUMAN ERYTHROPOIETIN DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Short-acting Recombinant Human Erythropoietin Drugs Market Size by Geographic Region (2021-2026)
4.1.1 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Short-acting Recombinant Human Erythropoietin Drugs Market Size by Country/Region (2021-2026)
4.2.1 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Sales by Country/Region (2021-2026)
4.2.2 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Revenue by Country/Region (2021-2026)
4.3 Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Growth
4.4 APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Growth
4.5 Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Growth
4.6 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Growth
5 AMERICAS
5.1 Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Country
5.1.1 Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2021-2026)
5.1.2 Americas Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2021-2026)
5.2 Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2021-2026)
5.3 Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Region
6.1.1 APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Region (2021-2026)
6.1.2 APAC Short-acting Recombinant Human Erythropoietin Drugs Revenue by Region (2021-2026)
6.2 APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2021-2026)
6.3 APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Short-acting Recombinant Human Erythropoietin Drugs by Country
7.1.1 Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2021-2026)
7.1.2 Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2021-2026)
7.2 Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2021-2026)
7.3 Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs by Country
8.1.1 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2021-2026)
8.1.2 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2021-2026)
8.2 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2021-2026)
8.3 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Short-acting Recombinant Human Erythropoietin Drugs
10.3 Manufacturing Process Analysis of Short-acting Recombinant Human Erythropoietin Drugs
10.4 Industry Chain Structure of Short-acting Recombinant Human Erythropoietin Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Short-acting Recombinant Human Erythropoietin Drugs Distributors
11.3 Short-acting Recombinant Human Erythropoietin Drugs Customer
12 WORLD FORECAST REVIEW FOR SHORT-ACTING RECOMBINANT HUMAN ERYTHROPOIETIN DRUGS BY GEOGRAPHIC REGION
12.1 Global Short-acting Recombinant Human Erythropoietin Drugs Market Size Forecast by Region
12.1.1 Global Short-acting Recombinant Human Erythropoietin Drugs Forecast by Region (2027-2032)
12.1.2 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Short-acting Recombinant Human Erythropoietin Drugs Forecast by Type (2027-2032)
12.7 Global Short-acting Recombinant Human Erythropoietin Drugs Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Amgen
13.1.1 Amgen Company Information
13.1.2 Amgen Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.1.3 Amgen Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Amgen Main Business Overview
13.1.5 Amgen Latest Developments
13.2 Johnson & Johnson
13.2.1 Johnson & Johnson Company Information
13.2.2 Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.2.3 Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Johnson & Johnson Main Business Overview
13.2.5 Johnson & Johnson Latest Developments
13.3 Roche
13.3.1 Roche Company Information
13.3.2 Roche Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.3.3 Roche Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Roche Main Business Overview
13.3.5 Roche Latest Developments
13.4 Kyowa Kirin
13.4.1 Kyowa Kirin Company Information
13.4.2 Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.4.3 Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Kyowa Kirin Main Business Overview
13.4.5 Kyowa Kirin Latest Developments
13.5 LG Chem
13.5.1 LG Chem Company Information
13.5.2 LG Chem Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.5.3 LG Chem Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 LG Chem Main Business Overview
13.5.5 LG Chem Latest Developments
13.6 Daewoong Pharmaceutical
13.6.1 Daewoong Pharmaceutical Company Information
13.6.2 Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.6.3 Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Daewoong Pharmaceutical Main Business Overview
13.6.5 Daewoong Pharmaceutical Latest Developments
13.7 Wockhardt
13.7.1 Wockhardt Company Information
13.7.2 Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.7.3 Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Wockhardt Main Business Overview
13.7.5 Wockhardt Latest Developments
13.8 CJ Healthcare
13.8.1 CJ Healthcare Company Information
13.8.2 CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.8.3 CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 CJ Healthcare Main Business Overview
13.8.5 CJ Healthcare Latest Developments
13.9 3SBio
13.9.1 3SBio Company Information
13.9.2 3SBio Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.9.3 3SBio Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 3SBio Main Business Overview
13.9.5 3SBio Latest Developments
13.10 Kexing Biopharm
13.10.1 Kexing Biopharm Company Information
13.10.2 Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.10.3 Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Kexing Biopharm Main Business Overview
13.10.5 Kexing Biopharm Latest Developments
13.11 Harbin Pharmaceutical Group
13.11.1 Harbin Pharmaceutical Group Company Information
13.11.2 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.11.3 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Harbin Pharmaceutical Group Main Business Overview
13.11.5 Harbin Pharmaceutical Group Latest Developments
13.12 Beijing Four Rings Bio-Pharmaceutical
13.12.1 Beijing Four Rings Bio-Pharmaceutical Company Information
13.12.2 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.12.3 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Beijing Four Rings Bio-Pharmaceutical Main Business Overview
13.12.5 Beijing Four Rings Bio-Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Short-acting Recombinant Human Erythropoietin Drugs by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Short-acting Recombinant Human Erythropoietin Drugs by Country/Region, 2021, 2025 & 2032
2.2 Short-acting Recombinant Human Erythropoietin Drugs Segment by Type
2.2.1 Epoetin-alfa
2.2.2 Epoetin-beta
2.2.3 Darbepoetin-alfa
2.2.4 Others
2.2.5 Short-acting Recombinant Human Erythropoietin Drugs Sales by Type
2.2.5.1 Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2021-2026)
2.2.5.2 Global Short-acting Recombinant Human Erythropoietin Drugs Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Type (2021-2026)
2.3 Short-acting Recombinant Human Erythropoietin Drugs Segment by Application
2.3.1 Anemia
2.3.2 Kidney Disorders
2.3.3 Others
2.3.4 Short-acting Recombinant Human Erythropoietin Drugs Sales by Application
2.3.4.1 Global Short-acting Recombinant Human Erythropoietin Drugs Sale Market Share by Application (2021-2026)
2.3.4.2 Global Short-acting Recombinant Human Erythropoietin Drugs Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Short-acting Recombinant Human Erythropoietin Drugs Breakdown Data by Company
3.1.1 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Sales by Company (2021-2026)
3.1.2 Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Company (2021-2026)
3.2 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Revenue by Company (2021-2026)
3.2.1 Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Company (2021-2026)
3.2.2 Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Company (2021-2026)
3.3 Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Company
3.4 Key Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Product Location Distribution
3.4.2 Players Short-acting Recombinant Human Erythropoietin Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR SHORT-ACTING RECOMBINANT HUMAN ERYTHROPOIETIN DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Short-acting Recombinant Human Erythropoietin Drugs Market Size by Geographic Region (2021-2026)
4.1.1 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Short-acting Recombinant Human Erythropoietin Drugs Market Size by Country/Region (2021-2026)
4.2.1 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Sales by Country/Region (2021-2026)
4.2.2 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Revenue by Country/Region (2021-2026)
4.3 Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Growth
4.4 APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Growth
4.5 Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Growth
4.6 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Growth
5 AMERICAS
5.1 Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Country
5.1.1 Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2021-2026)
5.1.2 Americas Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2021-2026)
5.2 Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2021-2026)
5.3 Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Region
6.1.1 APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Region (2021-2026)
6.1.2 APAC Short-acting Recombinant Human Erythropoietin Drugs Revenue by Region (2021-2026)
6.2 APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2021-2026)
6.3 APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Short-acting Recombinant Human Erythropoietin Drugs by Country
7.1.1 Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2021-2026)
7.1.2 Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2021-2026)
7.2 Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2021-2026)
7.3 Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs by Country
8.1.1 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2021-2026)
8.1.2 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2021-2026)
8.2 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2021-2026)
8.3 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Short-acting Recombinant Human Erythropoietin Drugs
10.3 Manufacturing Process Analysis of Short-acting Recombinant Human Erythropoietin Drugs
10.4 Industry Chain Structure of Short-acting Recombinant Human Erythropoietin Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Short-acting Recombinant Human Erythropoietin Drugs Distributors
11.3 Short-acting Recombinant Human Erythropoietin Drugs Customer
12 WORLD FORECAST REVIEW FOR SHORT-ACTING RECOMBINANT HUMAN ERYTHROPOIETIN DRUGS BY GEOGRAPHIC REGION
12.1 Global Short-acting Recombinant Human Erythropoietin Drugs Market Size Forecast by Region
12.1.1 Global Short-acting Recombinant Human Erythropoietin Drugs Forecast by Region (2027-2032)
12.1.2 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Short-acting Recombinant Human Erythropoietin Drugs Forecast by Type (2027-2032)
12.7 Global Short-acting Recombinant Human Erythropoietin Drugs Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Amgen
13.1.1 Amgen Company Information
13.1.2 Amgen Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.1.3 Amgen Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Amgen Main Business Overview
13.1.5 Amgen Latest Developments
13.2 Johnson & Johnson
13.2.1 Johnson & Johnson Company Information
13.2.2 Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.2.3 Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Johnson & Johnson Main Business Overview
13.2.5 Johnson & Johnson Latest Developments
13.3 Roche
13.3.1 Roche Company Information
13.3.2 Roche Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.3.3 Roche Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Roche Main Business Overview
13.3.5 Roche Latest Developments
13.4 Kyowa Kirin
13.4.1 Kyowa Kirin Company Information
13.4.2 Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.4.3 Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Kyowa Kirin Main Business Overview
13.4.5 Kyowa Kirin Latest Developments
13.5 LG Chem
13.5.1 LG Chem Company Information
13.5.2 LG Chem Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.5.3 LG Chem Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 LG Chem Main Business Overview
13.5.5 LG Chem Latest Developments
13.6 Daewoong Pharmaceutical
13.6.1 Daewoong Pharmaceutical Company Information
13.6.2 Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.6.3 Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Daewoong Pharmaceutical Main Business Overview
13.6.5 Daewoong Pharmaceutical Latest Developments
13.7 Wockhardt
13.7.1 Wockhardt Company Information
13.7.2 Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.7.3 Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Wockhardt Main Business Overview
13.7.5 Wockhardt Latest Developments
13.8 CJ Healthcare
13.8.1 CJ Healthcare Company Information
13.8.2 CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.8.3 CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 CJ Healthcare Main Business Overview
13.8.5 CJ Healthcare Latest Developments
13.9 3SBio
13.9.1 3SBio Company Information
13.9.2 3SBio Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.9.3 3SBio Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 3SBio Main Business Overview
13.9.5 3SBio Latest Developments
13.10 Kexing Biopharm
13.10.1 Kexing Biopharm Company Information
13.10.2 Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.10.3 Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Kexing Biopharm Main Business Overview
13.10.5 Kexing Biopharm Latest Developments
13.11 Harbin Pharmaceutical Group
13.11.1 Harbin Pharmaceutical Group Company Information
13.11.2 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.11.3 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Harbin Pharmaceutical Group Main Business Overview
13.11.5 Harbin Pharmaceutical Group Latest Developments
13.12 Beijing Four Rings Bio-Pharmaceutical
13.12.1 Beijing Four Rings Bio-Pharmaceutical Company Information
13.12.2 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.12.3 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Beijing Four Rings Bio-Pharmaceutical Main Business Overview
13.12.5 Beijing Four Rings Bio-Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Short-acting Recombinant Human Erythropoietin Drugs Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Short-acting Recombinant Human Erythropoietin Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Epoetin-alfa
Table 4. Major Players of Epoetin-beta
Table 5. Major Players of Darbepoetin-alfa
Table 6. Major Players of Others
Table 7. Global Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2021-2026) & (K Units)
Table 8. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2021-2026)
Table 9. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Type (2021-2026) & ($ million)
Table 10. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Type (2021-2026)
Table 11. Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global Short-acting Recombinant Human Erythropoietin Drugs Sale by Application (2021-2026) & (K Units)
Table 13. Global Short-acting Recombinant Human Erythropoietin Drugs Sale Market Share by Application (2021-2026)
Table 14. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Application (2021-2026) & ($ million)
Table 15. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Application (2021-2026)
Table 16. Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global Short-acting Recombinant Human Erythropoietin Drugs Sales by Company (2021-2026) & (K Units)
Table 18. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Company (2021-2026)
Table 19. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Company (2021-2026)
Table 21. Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Producing Area Distribution and Sales Area
Table 23. Players Short-acting Recombinant Human Erythropoietin Drugs Products Offered
Table 24. Short-acting Recombinant Human Erythropoietin Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Short-acting Recombinant Human Erythropoietin Drugs Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share Geographic Region (2021-2026)
Table 29. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Short-acting Recombinant Human Erythropoietin Drugs Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country/Region (2021-2026)
Table 33. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2021-2026) & (K Units)
Table 36. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country (2021-2026)
Table 37. Americas Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2021-2026) & (K Units)
Table 39. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2021-2026) & (K Units)
Table 40. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Region (2021-2026) & (K Units)
Table 41. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Region (2021-2026)
Table 42. APAC Short-acting Recombinant Human Erythropoietin Drugs Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2021-2026) & (K Units)
Table 44. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2021-2026) & (K Units)
Table 45. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2021-2026) & (K Units)
Table 46. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2021-2026) & (K Units)
Table 48. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Short-acting Recombinant Human Erythropoietin Drugs
Table 54. Key Market Challenges & Risks of Short-acting Recombinant Human Erythropoietin Drugs
Table 55. Key Industry Trends of Short-acting Recombinant Human Erythropoietin Drugs
Table 56. Short-acting Recombinant Human Erythropoietin Drugs Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Short-acting Recombinant Human Erythropoietin Drugs Distributors List
Table 59. Short-acting Recombinant Human Erythropoietin Drugs Customer List
Table 60. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas Short-acting Recombinant Human Erythropoietin Drugs Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC Short-acting Recombinant Human Erythropoietin Drugs Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Amgen Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 75. Amgen Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 76. Amgen Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Amgen Main Business
Table 78. Amgen Latest Developments
Table 79. Johnson & Johnson Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 80. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 81. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Johnson & Johnson Main Business
Table 83. Johnson & Johnson Latest Developments
Table 84. Roche Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 85. Roche Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 86. Roche Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Roche Main Business
Table 88. Roche Latest Developments
Table 89. Kyowa Kirin Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 90. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 91. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. Kyowa Kirin Main Business
Table 93. Kyowa Kirin Latest Developments
Table 94. LG Chem Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 95. LG Chem Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 96. LG Chem Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. LG Chem Main Business
Table 98. LG Chem Latest Developments
Table 99. Daewoong Pharmaceutical Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 100. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 101. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Daewoong Pharmaceutical Main Business
Table 103. Daewoong Pharmaceutical Latest Developments
Table 104. Wockhardt Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 105. Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 106. Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Wockhardt Main Business
Table 108. Wockhardt Latest Developments
Table 109. CJ Healthcare Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 110. CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 111. CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. CJ Healthcare Main Business
Table 113. CJ Healthcare Latest Developments
Table 114. 3SBio Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 115. 3SBio Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 116. 3SBio Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. 3SBio Main Business
Table 118. 3SBio Latest Developments
Table 119. Kexing Biopharm Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 120. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 121. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Kexing Biopharm Main Business
Table 123. Kexing Biopharm Latest Developments
Table 124. Harbin Pharmaceutical Group Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 125. Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 126. Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Harbin Pharmaceutical Group Main Business
Table 128. Harbin Pharmaceutical Group Latest Developments
Table 129. Beijing Four Rings Bio-Pharmaceutical Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 130. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 131. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. Beijing Four Rings Bio-Pharmaceutical Main Business
Table 133. Beijing Four Rings Bio-Pharmaceutical Latest Developments
Table 1. Short-acting Recombinant Human Erythropoietin Drugs Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Short-acting Recombinant Human Erythropoietin Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Epoetin-alfa
Table 4. Major Players of Epoetin-beta
Table 5. Major Players of Darbepoetin-alfa
Table 6. Major Players of Others
Table 7. Global Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2021-2026) & (K Units)
Table 8. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2021-2026)
Table 9. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Type (2021-2026) & ($ million)
Table 10. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Type (2021-2026)
Table 11. Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global Short-acting Recombinant Human Erythropoietin Drugs Sale by Application (2021-2026) & (K Units)
Table 13. Global Short-acting Recombinant Human Erythropoietin Drugs Sale Market Share by Application (2021-2026)
Table 14. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Application (2021-2026) & ($ million)
Table 15. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Application (2021-2026)
Table 16. Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global Short-acting Recombinant Human Erythropoietin Drugs Sales by Company (2021-2026) & (K Units)
Table 18. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Company (2021-2026)
Table 19. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Company (2021-2026)
Table 21. Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Producing Area Distribution and Sales Area
Table 23. Players Short-acting Recombinant Human Erythropoietin Drugs Products Offered
Table 24. Short-acting Recombinant Human Erythropoietin Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Short-acting Recombinant Human Erythropoietin Drugs Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share Geographic Region (2021-2026)
Table 29. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Short-acting Recombinant Human Erythropoietin Drugs Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country/Region (2021-2026)
Table 33. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2021-2026) & (K Units)
Table 36. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country (2021-2026)
Table 37. Americas Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2021-2026) & (K Units)
Table 39. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2021-2026) & (K Units)
Table 40. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Region (2021-2026) & (K Units)
Table 41. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Region (2021-2026)
Table 42. APAC Short-acting Recombinant Human Erythropoietin Drugs Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2021-2026) & (K Units)
Table 44. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2021-2026) & (K Units)
Table 45. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2021-2026) & (K Units)
Table 46. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2021-2026) & (K Units)
Table 48. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Short-acting Recombinant Human Erythropoietin Drugs
Table 54. Key Market Challenges & Risks of Short-acting Recombinant Human Erythropoietin Drugs
Table 55. Key Industry Trends of Short-acting Recombinant Human Erythropoietin Drugs
Table 56. Short-acting Recombinant Human Erythropoietin Drugs Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Short-acting Recombinant Human Erythropoietin Drugs Distributors List
Table 59. Short-acting Recombinant Human Erythropoietin Drugs Customer List
Table 60. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas Short-acting Recombinant Human Erythropoietin Drugs Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC Short-acting Recombinant Human Erythropoietin Drugs Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Amgen Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 75. Amgen Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 76. Amgen Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Amgen Main Business
Table 78. Amgen Latest Developments
Table 79. Johnson & Johnson Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 80. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 81. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Johnson & Johnson Main Business
Table 83. Johnson & Johnson Latest Developments
Table 84. Roche Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 85. Roche Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 86. Roche Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Roche Main Business
Table 88. Roche Latest Developments
Table 89. Kyowa Kirin Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 90. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 91. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. Kyowa Kirin Main Business
Table 93. Kyowa Kirin Latest Developments
Table 94. LG Chem Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 95. LG Chem Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 96. LG Chem Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. LG Chem Main Business
Table 98. LG Chem Latest Developments
Table 99. Daewoong Pharmaceutical Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 100. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 101. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Daewoong Pharmaceutical Main Business
Table 103. Daewoong Pharmaceutical Latest Developments
Table 104. Wockhardt Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 105. Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 106. Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Wockhardt Main Business
Table 108. Wockhardt Latest Developments
Table 109. CJ Healthcare Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 110. CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 111. CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. CJ Healthcare Main Business
Table 113. CJ Healthcare Latest Developments
Table 114. 3SBio Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 115. 3SBio Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 116. 3SBio Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. 3SBio Main Business
Table 118. 3SBio Latest Developments
Table 119. Kexing Biopharm Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 120. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 121. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Kexing Biopharm Main Business
Table 123. Kexing Biopharm Latest Developments
Table 124. Harbin Pharmaceutical Group Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 125. Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 126. Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Harbin Pharmaceutical Group Main Business
Table 128. Harbin Pharmaceutical Group Latest Developments
Table 129. Beijing Four Rings Bio-Pharmaceutical Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 130. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 131. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. Beijing Four Rings Bio-Pharmaceutical Main Business
Table 133. Beijing Four Rings Bio-Pharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Picture of Short-acting Recombinant Human Erythropoietin Drugs
Figure 2. Short-acting Recombinant Human Erythropoietin Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Short-acting Recombinant Human Erythropoietin Drugs Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country/Region (2025)
Figure 10. Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Epoetin-alfa
Figure 12. Product Picture of Epoetin-beta
Figure 13. Product Picture of Darbepoetin-alfa
Figure 14. Product Picture of Others
Figure 15. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type in 2026
Figure 16. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Type (2021-2026)
Figure 17. Short-acting Recombinant Human Erythropoietin Drugs Consumed in Anemia
Figure 18. Global Short-acting Recombinant Human Erythropoietin Drugs Market: Anemia (2021-2026) & (K Units)
Figure 19. Short-acting Recombinant Human Erythropoietin Drugs Consumed in Kidney Disorders
Figure 20. Global Short-acting Recombinant Human Erythropoietin Drugs Market: Kidney Disorders (2021-2026) & (K Units)
Figure 21. Short-acting Recombinant Human Erythropoietin Drugs Consumed in Others
Figure 22. Global Short-acting Recombinant Human Erythropoietin Drugs Market: Others (2021-2026) & (K Units)
Figure 23. Global Short-acting Recombinant Human Erythropoietin Drugs Sale Market Share by Application (2025)
Figure 24. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Application in 2026
Figure 25. Short-acting Recombinant Human Erythropoietin Drugs Sales by Company in 2026 (K Units)
Figure 26. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Company in 2026
Figure 27. Short-acting Recombinant Human Erythropoietin Drugs Revenue by Company in 2026 ($ millions)
Figure 28. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Company in 2026
Figure 29. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Geographic Region (2021-2026)
Figure 30. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Geographic Region in 2026
Figure 31. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales 2021-2026 (K Units)
Figure 32. Americas Short-acting Recombinant Human Erythropoietin Drugs Revenue 2021-2026 ($ millions)
Figure 33. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales 2021-2026 (K Units)
Figure 34. APAC Short-acting Recombinant Human Erythropoietin Drugs Revenue 2021-2026 ($ millions)
Figure 35. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales 2021-2026 (K Units)
Figure 36. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue 2021-2026 ($ millions)
Figure 37. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales 2021-2026 (K Units)
Figure 38. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue 2021-2026 ($ millions)
Figure 39. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country in 2026
Figure 40. Americas Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country (2021-2026)
Figure 41. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2021-2026)
Figure 42. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2021-2026)
Figure 43. United States Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 44. Canada Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 45. Mexico Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 46. Brazil Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 47. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Region in 2026
Figure 48. APAC Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Region (2021-2026)
Figure 49. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2021-2026)
Figure 50. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2021-2026)
Figure 51. China Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 52. Japan Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 53. South Korea Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 54. Southeast Asia Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 55. India Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 56. Australia Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 57. China Taiwan Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 58. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country in 2026
Figure 59. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country (2021-2026)
Figure 60. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2021-2026)
Figure 61. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2021-2026)
Figure 62. Germany Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 63. France Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 64. UK Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 65. Italy Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 66. Russia Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 67. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country (2021-2026)
Figure 68. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2021-2026)
Figure 69. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2021-2026)
Figure 70. Egypt Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 71. South Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 72. Israel Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 73. Turkey Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 74. GCC Countries Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Short-acting Recombinant Human Erythropoietin Drugs in 2026
Figure 76. Manufacturing Process Analysis of Short-acting Recombinant Human Erythropoietin Drugs
Figure 77. Industry Chain Structure of Short-acting Recombinant Human Erythropoietin Drugs
Figure 78. Channels of Distribution
Figure 79. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Forecast by Region (2027-2032)
Figure 80. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share Forecast by Region (2027-2032)
Figure 81. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share Forecast by Type (2027-2032)
Figure 82. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share Forecast by Type (2027-2032)
Figure 83. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share Forecast by Application (2027-2032)
Figure 84. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Short-acting Recombinant Human Erythropoietin Drugs
Figure 2. Short-acting Recombinant Human Erythropoietin Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Short-acting Recombinant Human Erythropoietin Drugs Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country/Region (2025)
Figure 10. Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Epoetin-alfa
Figure 12. Product Picture of Epoetin-beta
Figure 13. Product Picture of Darbepoetin-alfa
Figure 14. Product Picture of Others
Figure 15. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type in 2026
Figure 16. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Type (2021-2026)
Figure 17. Short-acting Recombinant Human Erythropoietin Drugs Consumed in Anemia
Figure 18. Global Short-acting Recombinant Human Erythropoietin Drugs Market: Anemia (2021-2026) & (K Units)
Figure 19. Short-acting Recombinant Human Erythropoietin Drugs Consumed in Kidney Disorders
Figure 20. Global Short-acting Recombinant Human Erythropoietin Drugs Market: Kidney Disorders (2021-2026) & (K Units)
Figure 21. Short-acting Recombinant Human Erythropoietin Drugs Consumed in Others
Figure 22. Global Short-acting Recombinant Human Erythropoietin Drugs Market: Others (2021-2026) & (K Units)
Figure 23. Global Short-acting Recombinant Human Erythropoietin Drugs Sale Market Share by Application (2025)
Figure 24. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Application in 2026
Figure 25. Short-acting Recombinant Human Erythropoietin Drugs Sales by Company in 2026 (K Units)
Figure 26. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Company in 2026
Figure 27. Short-acting Recombinant Human Erythropoietin Drugs Revenue by Company in 2026 ($ millions)
Figure 28. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Company in 2026
Figure 29. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Geographic Region (2021-2026)
Figure 30. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Geographic Region in 2026
Figure 31. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales 2021-2026 (K Units)
Figure 32. Americas Short-acting Recombinant Human Erythropoietin Drugs Revenue 2021-2026 ($ millions)
Figure 33. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales 2021-2026 (K Units)
Figure 34. APAC Short-acting Recombinant Human Erythropoietin Drugs Revenue 2021-2026 ($ millions)
Figure 35. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales 2021-2026 (K Units)
Figure 36. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue 2021-2026 ($ millions)
Figure 37. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales 2021-2026 (K Units)
Figure 38. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue 2021-2026 ($ millions)
Figure 39. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country in 2026
Figure 40. Americas Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country (2021-2026)
Figure 41. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2021-2026)
Figure 42. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2021-2026)
Figure 43. United States Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 44. Canada Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 45. Mexico Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 46. Brazil Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 47. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Region in 2026
Figure 48. APAC Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Region (2021-2026)
Figure 49. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2021-2026)
Figure 50. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2021-2026)
Figure 51. China Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 52. Japan Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 53. South Korea Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 54. Southeast Asia Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 55. India Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 56. Australia Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 57. China Taiwan Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 58. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country in 2026
Figure 59. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country (2021-2026)
Figure 60. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2021-2026)
Figure 61. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2021-2026)
Figure 62. Germany Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 63. France Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 64. UK Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 65. Italy Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 66. Russia Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 67. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country (2021-2026)
Figure 68. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2021-2026)
Figure 69. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2021-2026)
Figure 70. Egypt Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 71. South Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 72. Israel Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 73. Turkey Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 74. GCC Countries Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2021-2026 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Short-acting Recombinant Human Erythropoietin Drugs in 2026
Figure 76. Manufacturing Process Analysis of Short-acting Recombinant Human Erythropoietin Drugs
Figure 77. Industry Chain Structure of Short-acting Recombinant Human Erythropoietin Drugs
Figure 78. Channels of Distribution
Figure 79. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Forecast by Region (2027-2032)
Figure 80. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share Forecast by Region (2027-2032)
Figure 81. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share Forecast by Type (2027-2032)
Figure 82. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share Forecast by Type (2027-2032)
Figure 83. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share Forecast by Application (2027-2032)
Figure 84. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share Forecast by Application (2027-2032)
